Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL

Recruiting Phase 4 Interventional Study
Hypertensive Disorders of Pregnancy Preeclampsia Gestational Hypertension
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
14 – 35
Sex
Female
Trial phase
Phase 4
Study type
Interventional
Purpose
Prevention
Participants needed
10,742 (estimated)
Sponsor
Ohio State University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The overall goal of this large, pragmatic, comparative effectiveness trial is to test the hypothesis that among at-risk individuals, 162 mg/day aspirin is superior to 81 mg/day in preventing Hypertensive disorders of pregnancy (HDP), and that there are multiple factors associated with adherence with aspirin therapy that will be important to identify to enable optimal implementation of study findin…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. live intrauterine gestation ≤16 6/7 weeks gestational age based on best clinical obstetric estimate, 2. age 14 years or older and able to provide informed consent, 3. at least one of the following high-risk criteria: i) any prior pregnancy complicated by preeclampsia ii) curr…
Contacts

Maged Costantine, MD, MBA

614-293-2222

Maged.Costantine@osumc.edu

CONTACT

Kara Rood, MD

614-293-8045

Kara.Rood@osumc.edu

CONTACT